Med2Date — Clinical Guidelines
Home Analgesia Pain Types

Pain Types

Last updated 1 Jun 2026 · Pain & analgesia

📋 Key Information Summary

📋
  • Pain is mechanistically classified into nociceptive, neuropathic, nociplastic, and mixed categories; accurate classification guides analgesic selection.
  • Nociceptive pain arises from actual or threatened tissue damage activating peripheral nociceptors; examples include fracture, osteoarthritis, post-surgical pain, and visceral colic.
  • Neuropathic pain results from disease or lesion of the somatosensory nervous system; common causes in Australia include diabetic peripheral neuropathy (DPN), post-herpetic neuralgia (PHN), and spinal cord injury.
  • Nociplastic pain (previously "central sensitisation") arises from altered nociception without clear tissue damage or somatosensory lesion; fibromyalgia, irritable bowel syndrome, and non-specific chronic low back pain are prototypical.
  • Mixed pain combines two or more mechanisms (e.g., nociceptive + neuropathic in lumbar radiculopathy or cancer pain) and is the most common clinical presentation in chronic pain.
  • The DN4 questionnaire (≥4/10 suggests neuropathic pain) and painDETECT are validated screening tools recommended by the IASP and Australian Pain Society.
  • Nociceptive pain responds to simple analgesics (paracetamol, NSAIDs) and opioids; neuropathic pain requires adjuvant agents — first-line: amitriptyline, duloxetine, pregabalin, or gabapentin.
  • Nociplastic pain is best managed with multimodal non-pharmacological strategies (graded exercise, CBT, sleep hygiene) plus low-dose tricyclic antidepressants or SNRIs; opioids are ineffective and harmful.
  • Opioids have a limited role in chronic non-cancer pain (CNCP) across all pain types; the 2020 RACGP/ Faculty of Pain Medicine PMRI guidelines recommend against long-term opioid use for CNCP.
  • All neuropathic adjuvant analgesics require slow titration and renal/hepatic dose adjustment; PBS authority is required for pregabalin, duloxetine, and gabapentin for neuropathic pain.
  • Aboriginal and Torres Strait Islander Australians experience a 1.4-fold higher burden of chronic pain with significantly reduced access to specialist pain services; culturally safe, community-based models are essential.
  • Psychosocial contributors (yellow flags) must be assessed in every chronic pain presentation regardless of mechanism; untreated comorbid anxiety/depression worsens all pain types.
  • Re-assess pain classification at each visit — pain mechanisms can evolve over time, and treatment should be adjusted accordingly.

Introduction & Australian Epidemiology

Pain is the most common reason Australians seek healthcare. The International Association for the Study of Pain (IASP, 2020 revised definition) defines pain as "an unpleasant sensory and emotional experience associated with, or resembling that associated with, actual or potential tissue damage." Understanding the underlying mechanism of pain — rather than relying solely on duration (acute vs chronic) or anatomical location — is fundamental to rational analgesic prescribing and improved patient outcomes.

The IASP mechanistic classification recognises three primary categories: nociceptive, neuropathic, and nociplastic pain. In clinical practice, many patients present with mixed pain involving overlapping mechanisms. Accurate classification guides selection of analgesic classes, predicts treatment response, and helps set realistic patient expectations.

Australian Burden of Pain

  • Approximately 3.24 million Australians (1 in 5) live with chronic pain (persistent pain > 3 months), costing an estimated 9.3 billion annually in direct healthcare, lost productivity, and carer costs (Painaustralia / Deloitte Access Economics, 2019).
  • Neuropathic pain affects 7–10% of the general Australian population; post-herpetic neuralgia alone accounts for ~15,000 new cases per year.
  • Fibromyalgia (a nociplastic condition) is diagnosed in ~2–5% of Australians, with a female-to-male ratio of approximately 3:1.
  • Chronic low back pain — often mixed nociceptive/nociplastic — is the leading cause of disability in Australia (AIHW, 2023).
  • Aboriginal and Torres Strait Islander Australians experience chronic pain at 1.4 times the rate of non-Indigenous Australians, with markedly lower access to multidisciplinary pain management (AIHW, 2022).
  • The Australian Institute of Health and Welfare reports that opioid dispensing for chronic non-cancer pain remains high despite declining trends since 2018, underscoring the need for mechanism-based prescribing.
⚠️
Clinical imperative: Misclassifying pain mechanism is the most common cause of treatment failure in chronic pain. A patient with predominantly nociplastic pain prescribed escalating opioids will typically deteriorate, not improve. Always assess mechanism before escalating therapy.

Nociceptive Pain

Definition & Pathophysiology

Nociceptive pain arises from the activation of peripheral nociceptors (Aδ and C fibres) by actual or threatened tissue damage. Nociceptors transduce mechanical, thermal, or chemical stimuli into electrical signals that travel via the spinothalamic tract to the thalamus and somatosensory cortex. Inflammatory mediators (prostaglandins, bradykinin, substance P, TNF-α, IL-1β) sensitise peripheral nociceptors (peripheral sensitisation), lowering activation thresholds and amplifying pain signalling.

Nociceptive pain is typically proportional to the stimulus, well-localised, and described as aching, throbbing, or sharp. It serves a protective biological function and generally resolves with tissue healing.

Clinical Subtypes

Subtype Examples Characteristics
Somatic — superficial Skin laceration, burn, abrasion Sharp, well-localised, immediate onset
Somatic — deep Fracture, osteoarthritis, muscle strain, post-operative wound Aching, throbbing, worse with movement
Visceral Renal colic, appendicitis, mesenteric ischaemia, endometriosis Diffuse, poorly localised, may refer to dermatomes; nausea/vomiting common

Diagnostic Features

  • Pain consistent with identifiable tissue pathology (imaging, examination findings)
  • Proportional to nociceptive stimulus
  • Responsive to simple analgesics and anti-inflammatories
  • No neurological deficits (unless complicated by nerve compression)
  • DN4 score typically < 4/10

Pharmacological Management

💊
Paracetamol
Panadol® · Panamax® · Analgesic/antipyretic
Adult dose 500–1000 mg PO every 4–6 hours; max 4 g/day (≤2 g/day if >65 kg with hepatic risk)
Paediatric dose 15 mg/kg PO/PR every 4–6 hours; max 60 mg/kg/day
Renal adjustment eGFR 10–50: extend interval to every 6 hours; eGFR <10: every 8 hours
Hepatic adjustment Max 2 g/day in significant hepatic impairment; avoid in severe liver failure
PBS status ✔ PBS General Benefit
💊
Ibuprofen
Nurofen® · Brufen® · NSAID
Adult dose 200–400 mg PO every 6–8 hours; max 1200 mg/day (OTC) or 2400 mg/day (prescription)
Paediatric dose 5–10 mg/kg PO every 6–8 hours; max 30 mg/kg/day
Renal adjustment Avoid if eGFR <30 mL/min; use with caution if eGFR 30–60
Hepatic adjustment Avoid in severe hepatic impairment
PBS status ✔ PBS General Benefit
💊
Naproxen
Naprosyn® · Inza® · NSAID
Adult dose 250–500 mg PO every 12 hours; max 1000 mg/day
Paediatric dose 5–7 mg/kg PO every 12 hours (juvenile arthritis >2 years)
Renal adjustment Avoid if eGFR <30
Hepatic adjustment Use with caution; avoid in severe impairment
PBS status ✔ PBS General Benefit
🚨
NSAIDs safety: All NSAIDs (including topical diclofenac) increase cardiovascular risk and can precipitate acute kidney injury. Use the lowest effective dose for the shortest duration. Co-prescribe a PPI (e.g., omeprazole) for patients with GI risk factors. Avoid NSAIDs in heart failure (NYHA III–IV), eGFR <30, and third-trimester pregnancy.

Neuropathic Pain

Definition & Pathophysiology

Neuropathic pain is defined by the IASP as "pain caused by a lesion or disease of the somatosensory nervous system." It may be peripheral (affecting peripheral nerves, nerve roots, or dorsal root ganglia) or central (affecting the spinal cord or brain).

Key pathophysiological mechanisms include:

  • Ectopic nerve firing: Damaged nerves generate spontaneous action potentials without peripheral stimulus, often via upregulated sodium channels (Nav1.3, Nav1.7, Nav1.8).
  • Peripheral sensitisation: Increased excitability of intact nociceptors surrounding the lesion (inflammatory soup).
  • Central sensitisation: Increased excitability of dorsal horn neurons (wind-up phenomenon, NMDA receptor activation), leading to allodynia and hyperalgesia.
  • Loss of inhibitory interneurons: Reduced GABAergic/glycinergic tone in the dorsal horn, disinhibiting pain transmission.
  • Sympathetic coupling: Sympathetic efferents may interact with damaged sensory neurons, contributing to complex regional pain syndrome (CRPS).
  • Descending facilitation: Maladaptive changes in brainstem nuclei (periaqueductal grey, rostral ventromedial medulla) that normally inhibit spinal pain transmission.

Common Causes in Australian Practice

Peripheral Central
Diabetic peripheral neuropathy (DPN) Spinal cord injury / compression
Post-herpetic neuralgia (PHN) Post-stroke pain (thalamic)
Chemotherapy-induced peripheral neuropathy (CIPN) Multiple sclerosis
Trigeminal neuralgia Syringomyelia
Nerve entrapment (carpal tunnel, meralgia paraesthetica) Central post-stroke pain
HIV-associated neuropathy Parkinson's disease (rare)
Phantom limb pain

Clinical Features

Neuropathic pain is characterised by a distinct quality and sensory profile:

  • Burning, shooting, electric-shock, tingling, or "pins and needles"
  • Allodynia: pain from a normally non-painful stimulus (e.g., light touch, clothing on skin)
  • Hyperalgesia: exaggerated pain response to a normally painful stimulus
  • Paraesthesia / dysaesthesia: spontaneous unpleasant sensations
  • Often worse at night, disrupting sleep
  • Distribution follows a dermatomal or peripheral nerve pattern
  • Neurological examination may reveal sensory loss (pinprick, vibration, temperature) in the affected territory

Screening & Diagnostic Tools

The following validated tools assist identification of neuropathic pain components:

Essential DN4 Questionnaire (Douleur Neuropathique en 4) 7 sensory descriptors + 2 clinical examination items + 1 test (brush allodynia). Score ≥4/10 = probable neuropathic pain. Sensitivity 83%, specificity 90%.
Available painDETECT Questionnaire Self-administered, 9 items. Score ≤12 = nociceptive; ≥19 = neuropathic; 13–18 = ambiguous (mixed). Validated for DPN and low back pain.
Available LANSS Pain Scale 5 symptom items + 2 clinical examination items. Score ≥12 = neuropathic. Less validated in Australian primary care than DN4.
Specialist Nerve conduction studies / EMG Confirms peripheral nerve pathology; MBS item 11000 series. Useful for entrapment neuropathies, suspected large-fibre DPN.
Specialist Skin biopsy (intraepidermal nerve fibre density) Gold standard for small-fibre neuropathy diagnosis. Available at select Australian centres (not PBS-funded; out-of-pocket ~0–400).

Pharmacological Management — First-Line Agents

The following are recommended as first-line by the Australian Pain Society, Faculty of Pain Medicine (ANZCA), and Therapeutic Guidelines. Choice depends on comorbidities, side-effect profile, and patient preference.

💊
Amitriptyline
Endep® · Trypizol® · TCA
Mechanism Inhibits serotonin/noradrenaline reuptake; sodium channel blockade; NMDA antagonism
Adult dose Start 10 mg nocte; titrate by 10 mg every 1–2 weeks; target 25–75 mg nocte
Renal adjustment No specific adjustment; use with caution
Hepatic adjustment Reduce dose in hepatic impairment; avoid in severe liver disease
Key cautions Anticholinergic effects (dry mouth, constipation, urinary retention); cardiac conduction delays (avoid if QTc >470 ms); falls risk in elderly; contraindicated within 14 days of MAOIs
PBS status ✔ PBS General Benefit
💊
Duloxetine
Cymbalta® · SNRI
Mechanism Serotonin-noradrenaline reuptake inhibitor; enhances descending inhibitory pathways
Adult dose Start 30 mg OM for 1 week, then 60 mg OM; max 120 mg/day (rarely needed for pain)
Renal adjustment Avoid if eGFR <30 mL/min
Hepatic adjustment Avoid in severe hepatic impairment
Key cautions Nausea (most common, transient); serotonin syndrome risk with concurrent serotonergic agents; may elevate BP; avoid with MAOIs (14-day washout)
PBS status ⚠ PBS Authority Required — neuropathic pain
💊
Pregabalin
Lyrica® · α2δ ligand (gabapentinoid)
Mechanism Binds α2δ-1 subunit of voltage-gated calcium channels; reduces excitatory neurotransmitter release
Adult dose Start 75 mg BD; titrate to 150 mg BD after 3–7 days; max 300 mg BD (600 mg/day)
Paediatric dose Not TGA-approved <18 years for neuropathic pain
Renal adjustment eGFR 30–60: max 75–150 mg BD; eGFR 15–30: 25–75 mg OD–BD; eGFR <15: 25 mg OD; supplement dose post-HD
Key cautions Dizziness, somnolence, peripheral oedema, weight gain; risk of misuse/diversion (Schedule 4); taper over ≥1 week to discontinue
PBS status ⚠ PBS Authority Required — neuropathic pain (trials of TCA + one other first-line agent required)
💊
Gabapentin
Neurontin® · Aclonium® · α2δ ligand (gabapentinoid)
Adult dose Start 300 mg OD (nocte); titrate to 300 mg TDS over 1–2 weeks; effective range 900–3600 mg/day in divided doses
Paediatric dose 5–10 mg/kg/day in 2–3 divided doses, titrate up to 35 mg/kg/day (off-label)
Renal adjustment eGFR 30–59: 200–700 mg BD; eGFR 15–29: 200–700 mg OD; eGFR <15: 100–300 mg OD
Key cautions Non-linear absorption (bioavailability decreases at higher doses); dizziness, somnolence; taper to discontinue
PBS status ⚠ PBS Authority Required — neuropathic pain

Second-Line & Refractory Agents

💊
Tramadol
Tramal® · Tramadol hydrochloride · Weak opioid + SNRI
Adult dose 50–100 mg PO every 4–6 hours; max 400 mg/day
Renal adjustment eGFR <30: extend interval to every 12 hours; max 200 mg/day
Key cautions Seizure risk (lowered threshold); serotonin syndrome with SSRIs/MAOIs; CYP2D6 metabolism (poor metabolisers get less efficacy; ultra-rapid metabolisers risk toxicity)
PBS status ✔ PBS General Benefit
💊
Lamotrigine
Lamictal® · Anticonvulsant (sodium channel blocker)
Adult dose Start 25 mg OD for 2 weeks, then 50 mg OD for 2 weeks, titrate to 200 mg OD–BD
Key cautions Serious skin reactions (SJS/TEN) — slower titration required with concurrent valproate; educate patient re: rash
PBS status ✔ PBS General Benefit (for epilepsy; off-label for neuropathic pain)
💊
Capsaicin 8% patch
Qutenza® · Topical TRPV1 agonist
Dose Single application to affected area for 30–60 min by trained clinician; may repeat every 3 months
Indication Peripheral neuropathic pain (PHN, HIV neuropathy) — specialist application
PBS status ✘ Not PBS-listed — out-of-pocket ~0–400 per application
⚠️
Opioids and neuropathic pain: Strong opioids (morphine, oxycodone) are not recommended as first-line for neuropathic pain. Evidence shows modest short-term benefit with significant risk of harm (addiction, hyperalgesia, constipation, respiratory depression). Use only when first- and second-line agents have failed, at lowest effective dose, with clear functional goals and an exit strategy (RACGP/FPM Position Statement, 2020).

Nociplastic Pain

Definition & Pathophysiology

Nociplastic pain (IASP 2017) is "pain that arises from altered nociception despite no clear evidence of actual or threatened tissue damage causing the activation of peripheral nociceptors or evidence for disease or lesion of the somatosensory system causing the pain." Previously termed "central sensitisation" or "functional pain," it represents a shift in pain processing rather than structural pathology.

Key mechanisms include:

  • Central sensitisation: Amplified CNS processing of nociceptive signals with enhanced synaptic efficacy in dorsal horn neurons and thalamocortical networks.
  • Altered descending modulation: Impaired descending inhibition (reduced noradrenergic/serotonergic activity from brainstem) and/or enhanced descending facilitation.
  • Disrupted endogenous opioid function: Reduced μ-opioid receptor availability or altered endorphin/enkephalin release.
  • Neuroinflammation: Glial cell activation (microglia, astrocytes) in the CNS releasing pro-inflammatory cytokines that sustain pain amplification.
  • Psychoneuroimmune interactions: Stress, sleep deprivation, and psychological distress directly modulate immune and neural pain pathways.

Clinical Features — The Nociplastic Pain Phenotype

  • Widespread or diffuse pain disproportionate to identifiable pathology
  • Pain that does not follow a dermatomal or peripheral nerve distribution
  • Tenderness to palpation in multiple body regions (not just the primary site)
  • Associated symptoms: fatigue, unrefreshing sleep, cognitive difficulties ("fibro fog"), mood disturbance
  • Disproportionate sensitivity to environmental stimuli (noise, light, temperature)
  • Symptom flare triggered by stress, poor sleep, or weather changes
  • Poor response to conventional analgesics including opioids

Prototypical Nociplastic Conditions

Condition Key Features Diagnostic Criteria
Fibromyalgia Widespread pain >3 months, fatigue, sleep disturbance, cognitive symptoms ACR 2016: Widespread Pain Index (WPI) ≥7 + Symptom Severity Scale (SSS) ≥5, or WPI 3–6 + SSS ≥9
Irritable bowel syndrome (IBS) Abdominal pain related to defaecation, altered bowel habit Rome IV criteria: recurrent abdominal pain ≥1 day/week for ≥3 months
Chronic pelvic pain Pelvic pain >6 months; often co-occurs with endometriosis and bladder pain syndrome Clinical diagnosis of exclusion after investigation
Temporomandibular disorder (TMD) Jaw pain, clicking, restricted opening DC/TMD criteria
Chronic tension-type headache Bilateral pressing/tightening headache ≥15 days/month ICHD-3 criteria
Non-specific chronic low back pain Low back pain >3 months with no clear structural cause on imaging Clinical diagnosis; imaging only if red flags present

Pharmacological Management

Nociplastic pain responds poorly to conventional analgesics. Multimodal, primarily non-pharmacological strategies form the cornerstone, with pharmacotherapy as adjunctive.

💊
Duloxetine
Cymbalta® · SNRI — First-line for fibromyalgia
Adult dose 30 mg OM for 1 week, then 60 mg OM
Evidence NNT ≈ 7.2 for ≥50% pain reduction in fibromyalgia (Cochrane 2013)
PBS status ⚠ PBS Authority Required
💊
Amitriptyline
Endep® · TCA — First-line for fibromyalgia, chronic tension-type headache
Adult dose for nociplastic pain Start 5–10 mg nocte; titrate to 25–50 mg nocte
PBS status ✔ PBS General Benefit
💊
Pregabalin
Lyrica® · α2δ ligand — TGA-approved for fibromyalgia
Adult dose Start 75 mg BD; titrate to 150 mg BD over 1–2 weeks; max 450 mg/day
Evidence NNT ≈ 9 for ≥50% pain reduction in fibromyalgia; improves sleep quality
PBS status ⚠ PBS Authority Required
💊
Low-dose naltrexone
Compounded · Glial cell modulator (off-label)
Adult dose 1.5–4.5 mg PO nocte (compounded); titrate from 0.5 mg over 4–6 weeks
Evidence Emerging evidence for fibromyalgia, CRPS, chronic pelvic pain (small RCTs, NNT ~4); mechanism via glial cell TLR4 antagonism
PBS status ✘ Not PBS-listed — compounded; out-of-pocket ~–60/month

Non-Pharmacological Interventions (Core Management)

1
Graded Exercise Therapy
Low-impact aerobic exercise (walking, swimming, cycling) starting at 10–15 min, gradually increasing to 150 min/week. Strongest evidence base of any single intervention for fibromyalgia (Cochrane, NNT ~4).
2
Cognitive Behavioural Therapy (CBT)
Pain-focused CBT addressing catastrophising, fear-avoidance, and activity pacing. Available via GP Mental Health Treatment Plan (Medicare item 80110–80125; up to 10 sessions/year).
3
Sleep Hygiene & Management
Sleep disturbance perpetuates nociplastic pain; address with sleep hygiene education, treat comorbid OSA/RLS, avoid caffeine after midday, consistent wake time.
4
Patient Education & Self-Management
Pain neuroscience education (PNE) reframes pain as a nervous system output rather than tissue damage; reduces catastrophising and improves function. Flinders Chronic Condition Management Programme available in Australia.
5
Mindfulness & Acceptance-Based Approaches
Mindfulness-based stress reduction (MBSR) and acceptance and commitment therapy (ACT) have moderate evidence in chronic pain; available via some Australian pain management programmes.
🚨
Do NOT prescribe opioids for nociplastic pain. Opioids are ineffective for nociplastic mechanisms and cause harm: opioid-induced hyperalgesia worsens central sensitisation, dependence develops rapidly, and functional outcomes deteriorate. If a patient is already on long-term opioids, initiate a shared, slow taper (5–10% dose reduction every 2–4 weeks) with concurrent non-pharmacological support.

Mixed Pain

Definition

Mixed pain is the simultaneous presence of two or more mechanistic pain types in a single clinical syndrome. It is the most common presentation in chronic pain and is frequently encountered in primary care. The IASP recognises that pain mechanisms are not mutually exclusive and many conditions involve overlapping nociceptive, neuropathic, and nociplastic components.

Common Mixed Pain Syndromes in Australian Practice

Condition Nociceptive Component Neuropathic Component Nociplastic Component
Cancer pain Bone metastases, visceral infiltration, tumour mass effect Nerve compression/infiltration, chemotherapy-induced neuropathy, radiation plexopathy Central sensitisation from prolonged nociceptive input, psychosocial distress
Lumbar radiculopathy Disc herniation, facet joint arthropathy, muscle spasm Nerve root compression → dermatomal pain, paraesthesia, motor weakness Central sensitisation if pain persists >3 months; widespread hyperalgesia
Diabetic neuropathic pain with Charcot foot Fracture, joint destruction, soft tissue inflammation Peripheral neuropathy (sensory loss, burning pain) Altered central processing
Post-surgical chronic pain Ongoing tissue inflammation, mesh-related (hernia repair) Nerve entrapment (ilioinguinal, intercostal neuroma) Central sensitisation, pre-existing psychological vulnerability
Chronic knee osteoarthritis Cartilage loss, subchondral bone oedema, synovitis Peripheral nerve sensitisation (small-fibre pathology demonstrated in OA) Central sensitisation, widespread hyperalgesia, catastrophising
Endometriosis-related pain Peritoneal implants, adhesions, cyclical inflammation Nerve infiltration by endometriotic lesions (sciatic, pudendal) Central sensitisation with persistent symptoms despite hormonal suppression

Clinical Approach to Mixed Pain

1
Identify Proportion of Each Mechanism
Use DN4, painDETECT, clinical examination, and imaging to estimate the relative contribution of each mechanism. Ask: "How much of this pain is burning/tingling (neuropathic) versus aching/throbbing (nociceptive) versus widespread/fatigue-associated (nociplastic)?"
2
Treat the Dominant Mechanism First
If neuropathic features dominate, start a TCA, SNRI, or gabapentinoid. If nociceptive features dominate, optimise simple analgesics ± NSAIDs. If nociplastic features dominate, prioritise non-pharmacological strategies.
3
Combine Mechanism-Specific Agents
Combining agents from different mechanistic classes (e.g., paracetamol + amitriptyline + duloxetine) is rational in mixed pain and often more effective than dose escalation of a single agent. Avoid combining two gabapentinoids.
4
Address Psychosocial Factors
Yellow flags (catastrophising, fear-avoidance, secondary gain, comorbid depression/anxiety) are present in most chronic mixed pain and predict poor outcomes. Screen with PHQ-9, GAD-7, and Pain Catastrophising Scale. Refer for psychological intervention.
5
Refer to Multidisciplinary Pain Service
Complex mixed pain warrants referral to a multidisciplinary pain management programme (pain specialist, psychologist, physiotherapist, occupational therapist). Available via public hospital pain clinics in all Australian states (wait 3–12 months); private with Medicare rebate. MBS item 18260 (specialist consultation).

Cancer Pain — A Mixed Pain Paradigm

Cancer pain exemplifies mixed pain and requires a WHO analgesic ladder–based approach modified by mechanism:

WHO Ladder Step Nociceptive Component Neuropathic Component
Step 1 — Mild pain (NRS 1–3) Paracetamol ± NSAID Add adjuvant (amitriptyline, gabapentin, duloxetine)
Step 2 — Moderate pain (NRS 4–6) Add weak opioid (tramadol, codeine) or low-dose strong opioid Escalate adjuvant; consider corticosteroid for nerve compression
Step 3 — Severe pain (NRS 7–10) Strong opioid (morphine, oxycodone, fentanyl) + adjuvants High-dose adjuvant ± ketamine (specialist), nerve block, radiation therapy
💡
Quick reference — Which analgesic for which mechanism? Nociceptive → paracetamol, NSAIDs, opioids (short-term). Neuropathic → TCAs, SNRIs, gabapentinoids, topical lidocaine/capsaicin. Nociplastic → graded exercise, CBT, TCAs/SNRIs. Mixed → combine strategies targeting each identified mechanism.
Pain Mechanism
First-Line Drug Class
Expected Response
Key Consideration
Nociceptive (acute)
Paracetamol ± NSAID
Hours to days
NSAID: shortest duration; PPI if GI risk
Neuropathic (peripheral)
TCA or SNRI or gabapentinoid
2–6 weeks
Slow titration; renal dose adjustment
Nociplastic
Exercise + CBT ± amitriptyline/duloxetine
6–12 weeks
Opioids contraindicated; expect slow gains
Mixed (chronic)
Multimodal — combine above
Ongoing
Re-assess mechanism at each visit; MDT referral

Pathophysiology — Integrative Overview

Understanding the nociceptive pathway from periphery to cortex clarifies where each pain mechanism disrupts normal processing:

Step 1
Transduction (periphery): Tissue damage releases inflammatory mediators (PGE₂, bradykinin, serotonin, H⁺, ATP) that activate TRPV1, TRPA1, and ASIC channels on Aδ and C fibre terminals. Disrupted in nociceptive pain (amplified by inflammation) and nociplastic pain (sensitised in absence of ongoing tissue damage).
Step 2
Transmission (peripheral nerve → dorsal horn): Action potentials propagate along Aδ (sharp, first pain) and C fibres (dull, second pain) to laminae I–V of the spinal dorsal horn. Glutamate (AMPA, NMDA) and substance P mediate synaptic transmission. Disrupted in neuropathic pain (ectopic firing, sodium channel upregulation) and nociplastic pain (wind-up, NMDA-mediated central sensitisation).
Step 3
Modulation (descending pathways): Brainstem nuclei (PAG, RVM) exert bidirectional control via noradrenergic (locus coeruleus) and serotonergic (nucleus raphe magnus) projections to the dorsal horn. Endogenous opioids (endorphins, enkephalins, dynorphins) suppress pain at multiple levels. Impaired in nociplastic pain (reduced descending inhibition) and chronic neuropathic pain (enhanced descending facilitation).
Step 4
Perception (cortex): Thalamocortical projections to S1/S2 (sensory-discriminative), anterior cingulate cortex and insula (affective-motivational), and prefrontal cortex (cognitive-evaluative) generate the conscious pain experience. Psychological state, prior experience, and expectations profoundly modulate perception. Central to nociplastic pain and the biopsychosocial model of chronic pain.

Biomarkers & Emerging Diagnostics

  • Conditioned pain modulation (CPM): Quantitative sensory testing (QST) paradigm measuring endogenous analgesia; reduced CPM predicts nociplastic phenotype and poor opioid response. Available at some Australian research pain centres (not routine clinical practice).
  • Functional MRI (fMRI): Demonstrates altered brain connectivity (default mode network, salience network) in nociplastic pain; research tool only.
  • Genetic polymorphisms: COMT, SCN9A, OPRM1 variants influence pain sensitivity and analgesic response; not yet clinically validated for routine use in Australia.

Investigations

Investigations in pain assessment should be guided by the suspected mechanism and should always include screening for underlying causes and treatable contributors.

Essential Full blood count (FBC) Screen for haematological causes, malignancy, infection. MBS item 65070.
Essential Erythrocyte sedimentation rate (ESR) / C-reactive protein (CRP) Inflammatory markers; elevated in nociceptive/inflammatory conditions, polymyalgia rheumatica, giant cell arteritis. MBS item 65070.
Essential HbA1c / fasting glucose Screen for diabetes mellitus as cause of peripheral neuropathy. MBS item 65070.
Essential Thyroid function tests (TSH, fT4) Hypothyroidism causes diffuse myalgia/arthralgia; carpal tunnel association. MBS item 65070.
Available Vitamin B12, folate, vitamin D (25-OH) B12 deficiency causes peripheral neuropathy; vitamin D deficiency associated with chronic widespread pain. MBS item 65070 (B12, folate); vitamin D MBS item 66822 (if clinical indication).
Available Serum protein electrophoresis (SPEP) Screen for paraproteinaemia (POEMS syndrome, myeloma) as cause of neuropathic pain. MBS item 65100.
Available X-ray (affected area) Structural assessment for osteoarthritis, fracture, joint effusion. MBS item 58100 (single region). Not indicated for non-specific low back pain in the first 6 weeks without red flags.
Available MRI (lumbar spine, brain, affected region) Assessment of disc herniation, nerve root compression, spinal cord lesion, central causes. MBS item 63001 (MRI lumbar spine with referral). Wait times 1–4 weeks (public); 1–5 days (private).
Specialist Nerve conduction studies / electromyography (NCS/EMG) Gold standard for large-fibre neuropathy and entrapment neuropathies. MBS item 11000 series. Wait 2–8 weeks in public; 1–2 weeks private. Not reliable for small-fibre neuropathy.
Specialist Quantitative sensory testing (QST) Standardised assessment of sensory thresholds (warmth, cold, vibration, pressure pain). Research/specialist tool — available at select university pain centres. Not MBS-funded.
Specialist Skin punch biopsy (intraepidermal nerve fibre density — IENFD) Gold standard for small-fibre neuropathy. 3 mm punch biopsy from distal leg. Available at dermatology/pathology services. Out-of-pocket ~0–400. Not MBS-funded.

Special Populations

🤰

Pregnancy

Paracetamol Analgesic of choice in all trimesters; standard doses
NSAIDs Contraindicated in third trimester (premature ductus arteriosus closure, oligohydramnios). Use with caution 1st/2nd trimester; avoid prolonged use.
Amitriptyline Category C; use only if benefits outweigh risks. Avoid in third trimester (neonatal withdrawal).
Duloxetine Category B3; limited human data. Avoid if possible; neonatal withdrawal reported.
Pregabalin Category B3; avoid unless essential. Limited safety data.
Gabapentin Category B1; limited data. Prefer paracetamol ± physical therapies first.
Opioids Short-term use acceptable; chronic use risks neonatal abstinence syndrome. Codeine contraindicated in breastfeeding (CYP2D6 ultra-rapid metaboliser risk).
👶

Paediatrics

Paracetamol 15 mg/kg PO/PR every 4–6 hours; max 60 mg/kg/day. First-line for acute pain.
Ibuprofen 5–10 mg/kg every 6–8 hours. Avoid in dehydrated children.
Amitriptyline Used off-label for neuropathic pain/functional abdominal pain. Start 0.1–0.2 mg/kg nocte, titrate slowly. Specialist supervision recommended for <12 years.
Gabapentin Off-label; 5–10 mg/kg/day in 2–3 divided doses, titrate to 35 mg/kg/day. Used for neuropathic pain in paediatric pain clinics.
Pregabalin Not TGA-approved <18 years. Use only under specialist guidance.
Key consideration Adolescent chronic pain is commonly nociplastic/mixed; emphasis on school re-engagement, graded activity, family-based CBT. Refer to paediatric chronic pain service (available at major children's hospitals).
🧓

Elderly (≥65 years)

Paracetamol First-line; max 2 g/day if frailty or hepatic concerns. Avoid combination products (e.g., cold/flu preparations) to prevent inadvertent overdose.
NSAIDs Avoid if possible — high GI bleed, renal, and cardiovascular risk. If essential: naproxen + PPI, shortest duration. BEERS criteria list NSAIDs as potentially inappropriate in older adults.
Amitriptyline Start very low (2.5–5 mg nocte). Falls, confusion, urinary retention, constipation are major concerns. BEERS criteria — avoid if possible; consider alternatives (duloxetine, gabapentin with renal adjustment).
Pregabalin / Gabapentin Dizziness, somnolence, falls risk, peripheral oedema. Start low, go slow. Renal dose adjustment mandatory.
Opioids Increased sensitivity; higher risk of falls, confusion, constipation, respiratory depression. If required: start at 50% of standard adult dose, titrate slowly. Avoid codeine (constipation, variable metabolism), tramadol (falls, seizures, serotonin syndrome), and pethidine entirely.
🫘

Renal Impairment

Paracetamol Preferred analgesic; extend interval (every 6–8 hours in severe impairment). Dose reduction not required but monitor.
NSAIDs Avoid if eGFR <30. Risk of acute kidney injury, hyperkalaemia, fluid retention. If eGFR 30–60: short course only with monitoring.
Gabapentinoids Gabapentin: extensive renal dose adjustment required. Pregabalin: dose reduction by ≥50% if eGFR <60; eGFR <15: 25 mg OD. Both cleared by HD — supplement post-dialysis.
Duloxetine Avoid if eGFR <30.
Opioids Avoid morphine (active metabolites M6G accumulate); tramadol dose reduce. Preferred: fentanyl or buprenorphine (less renally cleared). Oxycodone: dose reduce, extended interval.
🫁

Hepatic Impairment

Paracetamol Max 2 g/day in significant hepatic impairment (Child-Pugh B/C); avoid in acute liver failure.
NSAIDs Avoid in severe hepatic impairment (coagulopathy, portal hypertension).
Amitriptyline Hepatically metabolised; reduce dose in moderate impairment; avoid in severe impairment.
Duloxetine Avoid in any hepatic impairment — significant first-pass metabolism, risk of hepatotoxicity.
Opioids All opioids metabolised hepatically; dose reduction and extended intervals required. Tramadol and codeine: variable metabolism; avoid. Morphine: use cautiously. Fentanyl/buprenorphine preferred with dose reduction.
🛡️

Immunocompromised

Key considerations Higher index of suspicion for infection (osteomyelitis, discitis, CMV polyneuropathy) as a cause of pain. Always exclude treatable infectious causes before classifying pain as chronic.
Chemotherapy-induced peripheral neuropathy (CIPN) Common with vincristine, paclitaxel, cisplatin, oxaliplatin. Duloxetine has best evidence (ASCO guidelines) for treatment. Prevention: no established agent (ASCO recommends against routine use of any preventive agent).
HIV-associated neuropathy Distal symmetric polyneuropathy is most common neurological complication of HIV. Treat with duloxetine or amitriptyline; topical capsaicin 8% patch. Review antiretrovirals (ddI, d4T — historical, rarely used now).

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health

Chronic pain is a significant and under-recognised health burden for Aboriginal and Torres Strait Islander Australians. The 2018–19 National Aboriginal and Torres Strait Islander Health Survey found that 27% of Indigenous Australians reported chronic pain, compared with 19% of non-Indigenous Australians — a 1.4-fold excess burden. Despite this higher prevalence, access to specialist pain management, allied health services, and culturally appropriate care is markedly lower, particularly in remote and very remote communities.

Key Factors Contributing to Pain Burden

Higher prevalence of chronic disease
Diabetes (3× higher rates), renal disease, musculoskeletal conditions, and trauma contribute to higher rates of nociceptive and neuropathic pain. Diabetic peripheral neuropathy is a major contributor to neuropathic pain burden.
Remote access barriers
Specialist pain services, multidisciplinary teams, and allied health (physiotherapy, psychology) are concentrated in major cities. Remote communities may have a visiting GP and no pain specialist, psychologist, or pharmacist within hundreds of kilometres.
Cultural concepts of pain
Pain may be understood within a holistic framework encompassing spiritual, social, and emotional dimensions, not solely biomedical. Western pain scales (NRS, VAS) may not capture the full experience. Yarning-based approaches to pain assessment are more culturally appropriate.
Communication and health literacy
English may not be a first language for many community members, particularly in remote areas. Health literacy levels may be lower, and written pain questionnaires (DN4, painDETECT) may require translation, visual aids, or administration by Aboriginal Health Workers/Practitioners (AHW/AHP).
Intergenerational trauma
The impacts of colonisation, forced removal, and systemic racism contribute to psychosocial distress that amplifies nociplastic pain mechanisms. Trauma-informed care is essential in all pain management interactions.
Opioid prescribing disparities
Indigenous Australians are disproportionately prescribed opioids for chronic pain, often without access to non-pharmacological alternatives. The PBS opioid reforms (2020) and real-time prescription monitoring (SafeScript / SafeScript NSW) may inadvertently create barriers to timely access for patients with genuine need in remote areas.

Culturally Safe Pain Management Strategies

  • Aboriginal Health Workers/Practitioners (AHW/AHP): Engage AHW/AHP as key members of the pain management team. They provide culturally safe education, facilitate communication, support medication adherence, and act as a bridge between Western biomedical and Indigenous health frameworks. Funded under MBS item 715 (health check) and 721 (GP Management Plan).
  • Yarning-based pain assessment: Use conversational, narrative-based assessment ("Can you tell me about your pain?") rather than formal questionnaires. Explore impact on cultural activities, community obligations, and connection to Country.
  • Telehealth pain management: The Australian Government's telehealth MBS items (video consultation items 99200–99215) enable specialist pain consultations in remote communities. Several state pain services (e.g., NSW Agency for Clinical Innovation Pain Management Network, SA Pain Management Network) offer rural/remote telehealth pathways.
  • Community-based models: The Central Australian Rural Practitioners Association (CARPA) Standard Treatment Manual provides culturally adapted pain guidelines for remote NT. The Lowitja Institute supports Indigenous health research including chronic pain.
  • Addressing yellow flags within a cultural context: Fear-avoidance, catastrophising, and social withdrawal may manifest differently. Koori/Aboriginal community-controlled health organisations (ACCHOs) can provide integrated pain and social-emotional wellbeing support.
  • Medication access in remote communities: Remote Area Aboriginal Health Services (RAAHS) stock essential analgesics including paracetamol, amitriptyline, gabapentin, and tramadol. Pregabalin and duloxetine (authority-required) may face delays; pre-approval through PBS authority phone line (1800 888 333) can facilitate timely access.
  • Close the Gap — pain management equity: Pain management should be embedded in chronic disease management strategies aligned with the National Agreement on Closing the Gap (2020), particularly Priority Reform 1 (formal partnerships) and Priority Reform 2 (community-controlled sector building).
✅
Best practice: Every Aboriginal and Torres Strait Islander patient presenting with pain should have a structured assessment that includes a culturally safe exploration of pain impact, access barriers, and preferred management approaches. Use MBS Item 715 (Aboriginal and Torres Strait Islander health check) and MBS Items 721/723 (GP Management Plans/Team Care Arrangements) to fund coordinated, multidisciplinary care.

📚 References

  1. 1. International Association for the Study of Pain (IASP). Revised IASP definition of pain (2020). Pain. 2020;161(9):1976–1982. doi:10.1097/j.pain.0000000000001939
  2. 2. Kosek E, Cohen M, Baron R, et al. Do we need a third mechanistic descriptor for chronic pain states? Pain. 2016;157(7):1382–1386. doi:10.1097/j.pain.0000000000000507
  3. 3. Bouhassira D, Attal N, Alchaar H, et al. Comparison of pain syndromes associated with nervous or somatosomatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain. 2005;114(1–2):29–36.
  4. 4. Freynhagen R, Tölle TR, Gockel U, Baron R. The painDETECT project — far more than a screening tool on neuropathic pain. Curr Med Res Opin. 2016;32(6):1033–1057.
  5. 5. Painaustralia. The Cost of Pain in Australia. Deloitte Access Economics; 2019. Available at: painaustralia.org.au
  6. 6. Australian Institute of Health and Welfare (AIHW). Chronic pain in Australia. Cat. no. PHE 267. Canberra: AIHW; 2020.
  7. 7. The Royal Australian College of General Practitioners (RACGP) and Faculty of Pain Medicine, Australian and New Zealand College of Anaesthetists (FPM ANZCA). Prescription Opioid Policy: Improving management of chronic non-malignant pain and prevention of problems associated with opioid use. Melbourne: RACGP; 2020.
  8. 8. Australian Pain Society. Position Statement: Use of Medicines for the Management of Chronic Pain. Sydney: Australian Pain Society; 2020.
  9. 9. Wolfe F, Clauw DJ, Fitzcharles MA, et al. 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheum. 2016;46(3):319–329.
  10. 10. Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162–173.
  11. 11. Derry S, Wiffen PJ, Aldington D, Moore RA. Nortriptyline for neuropathic pain in adults. Cochrane Database Syst Rev. 2015;(1):CD011209.
  12. 12. Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy or chronic pain. Cochrane Database Syst Rev. 2014;(10):CD007115.
  13. 13. Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ. Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev. 2009;(3):CD007076.
  14. 14. Hooten WM. Chronic pain and mental health disorders: shared neural mechanisms, epidemiology, and treatment. Mayo Clin Proc. 2016;91(7):955–970.
  15. 15. National Aboriginal Community Controlled Health Organisation (NACCHO). National Aboriginal and Torres Strait Islander Health Plan 2021–2031. Canberra: Commonwealth of Australia; 2021.
  16. 16. Central Australian Rural Practitioners Association (CARPA). Standard Treatment Manual. 7th ed. Alice Springs: CARPA; 2017.
  17. 17. Fitzcharles MA, Cohen SP, Clauw DJ, Littlejohn G, Usui C, Bhamb B. Nociplastic pain: towards an understanding of prevalent pain conditions. Lancet. 2021;397(10289):2098–2110.
  18. 18. ASCO Guideline: Management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers. J Clin Oncol. 2020;38(28):3325–3348. doi:10.1200/JCO.20.01399
for PBS scripts. Utilise ACCHS pharmacies and Remote Area Aboriginal Health Worker programs for medication supply in remote areas. Avoid initiating benzodiazepines; support holistic pain management including community-based exercise programs.
Preventive health
Promote bone health: encourage vitamin D supplementation (1000 IU daily in deficient individuals), smoking cessation support, reduction of alcohol intake, and weight-bearing exercise. MBS Item 715 health checks provide a structured opportunity to assess bone health, screen for osteoporosis risk factors, and discuss musculoskeletal health in a culturally safe context.

Quick Reference: Differential Diagnosis at a Glance

Costovertebral dysfunction
Paracetamol ± NSAID; manual therapy
2–6 weeks
Provocable on palpation; no red flags
Thoracic compression fracture
Paracetamol; ± calcitonin; DXA + osteoporosis Rx
6–12 weeks healing
Elderly; osteoporosis; acute onset
ACS (posterior MI)
Aspirin 300 mg, GTN, heparin; urgent PCI
Time-critical
ECG, troponin; CV risk factors
Aortic dissection
IV labetalol; urgent CT aortogram; surgery (Type A)
Time-critical
Tearing pain; BP differential >20 mmHg
Vertebral osteomyelitis
IV antibiotics (vancomycin + ceftriaxone initially); ID consult
6 weeks IV antibiotics
Fever, elevated CRP, IV drug use
Biliary colic / cholecystitis
Paracetamol ± morphine; lap cholecystectomy
Surgical within 72 h (cholecystitis)
RUQ/infrascapular; post-prandial; RUQ US

📚 References

  1. 1. Briggs AM, Smith AJ, Straker LM, Bragge P. Thoracic spine pain in the general population: prevalence, incidence and associated factors in children, adolescents and adults. A systematic review. BMC Musculoskelet Disord. 2009;10:77.
  2. 2. National Health and Medical Research Council (NHMRC). Evidence-based management of acute musculoskeletal pain. Canberra: NHMRC; 2003 (updated 2020).
  3. 3. Australian Institute of Health and Welfare (AIHW). Aboriginal and Torres Strait Islander Health Performance Framework: Summary report 2023. Canberra: AIHW; 2023.
  4. 4. Deyo RA, Rainville J, Kent DL. What can the history and physical examination tell us about low back pain? JAMA. 1992;268(6):760–765.
  5. 5. Stochkendahl MJ, Kjaer P, Hartvigsen J, et al. National Clinical Guidelines for non-surgical treatment of patients with recent onset low back pain or lumbar radiculopathy. Europ Spine J. 2018;27(1):60–75.
  6. 6. Erwin WM, Jackson PC, Homonko DA. Innervation of the human costovertebral joint: implications for clinical back pain syndromes. J Manipulative Physiol Ther. 2000;23(6):395–403.
  7. 7. Royal Australian College of General Practitioners (RACGP). Guidelines for preventive activities in general practice. 9th edn. Melbourne: RACGP; 2018 (updated 2023).
  8. 8. Hirsch JA, Singh V, Falco FJE, et al. Thoracic facet joint interventions. Pain Physician. 2016;19(4):E581–E593.
  9. 9. Erwin WM, Jackson PC. The costovertebral joint: anatomy, biomechanics, and clinical significance in thoracic back pain syndromes. J Can Chiropr Assoc. 2003;47(2):112–120.
  10. 10. Strayer RJ, Gunnerson JM, Brown LH, et al. Aortic dissection: clinical features, diagnosis, and management. Aust Crit Care. 2019;32(2):144–153.
  11. 11. Ombregt L. A system of orthopaedic medicine. 3rd edn. Edinburgh: Churchill Livingstone Elsevier; 2013. Chapter 18: Thoracic spine.
  12. 12. Lin CC, Chen KH, Li DM, et al. Characteristics and outcomes of patients presenting with thoracic back pain to the emergency department. Emerg Med Australas. 2020;32(5):805–811.
for PBS-listed medicines at participating pharmacies.
Cultural safety
Engagement with Aboriginal Community Controlled Health Organisations (ACCHOs) is essential. Cultural safety training for non-Indigenous clinicians, use of Aboriginal Health Workers and Liaison Officers, and incorporation of traditional healing practices alongside Western medicine improve treatment adherence and outcomes. Avoidance of eye contact, respect for gender-sensitive examination practices, and understanding of sorry business protocols are critical elements of culturally safe care.
Medication adherence
Complex DMARD regimens with frequent monitoring requirements present adherence challenges. Long-acting depot injections (e.g., methotrexate SC) may improve adherence compared to oral regimens. Community pharmacy partnerships through the Indigenous Pharmacy Programmes improve medication management.
Specific conditions
Rheumatic heart disease (RHD) requires secondary prophylaxis with benzathine penicillin G (BPG) 1.2 MU IM every 3–4 weeks for a minimum of 10 years or until age 21 (whichever is longer). RHD registers (e.g., NT RHD Register) facilitate recall and follow-up. The Australian RHD Endgame Strategy targets elimination by 2031.
Referral pathways
Referral through ACCHOs and Aboriginal Hospital Liaison Officers (AHLOs) improves engagement. The Specialist Outreach Assistance Programme provides funded specialist visits to remote communities. NT, WA, and QLD have specific rheumatology outreach programmes targeting Indigenous communities.

📚 References

  1. 1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
  2. 2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939.
  3. 3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
  4. 4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583–1599.
  5. 5. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
  6. 6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
  7. 7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
  8. 8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
  9. 9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487–1498.
  10. 10. Pisetsky DS. Antinuclear antibody testing — misunderstood or misused? Clin Immunol. 2023;255:109717.
  11. 11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
  12. 12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155–158.
  13. 13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).
for PBS-listed medicines at participating pharmacies.
Cultural safety
Engagement with Aboriginal Community Controlled Health Organisations (ACCHOs) is essential. Cultural safety training for non-Indigenous clinicians, use of Aboriginal Health Workers and Liaison Officers, and incorporation of traditional healing practices alongside Western medicine improve treatment adherence and outcomes. Avoidance of eye contact, respect for gender-sensitive examination practices, and understanding of sorry business protocols are critical elements of culturally safe care.
Medication adherence
Complex DMARD regimens with frequent monitoring requirements present adherence challenges. Long-acting depot injections (e.g., methotrexate SC) may improve adherence compared to oral regimens. Community pharmacy partnerships through the Indigenous Pharmacy Programmes improve medication management.
Specific conditions
Rheumatic heart disease (RHD) requires secondary prophylaxis with benzathine penicillin G (BPG) 1.2 MU IM every 3–4 weeks for a minimum of 10 years or until age 21 (whichever is longer). RHD registers (e.g., NT RHD Register) facilitate recall and follow-up. The Australian RHD Endgame Strategy targets elimination by 2031.
Referral pathways
Referral through ACCHOs and Aboriginal Hospital Liaison Officers (AHLOs) improves engagement. The Specialist Outreach Assistance Programme provides funded specialist visits to remote communities. NT, WA, and QLD have specific rheumatology outreach programmes targeting Indigenous communities.

📚 References

  1. 1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
  2. 2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939.
  3. 3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
  4. 4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583–1599.
  5. 5. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
  6. 6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
  7. 7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
  8. 8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
  9. 9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487–1498.
  10. 10. Pisetsky DS. Antinuclear antibody testing — misunderstood or misused? Clin Immunol. 2023;255:109717.
  11. 11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
  12. 12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155–158.
  13. 13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).